| Ticker: | ALXO |
| Current Price: | $1.04 |
| % Daily Change: | -3.70% |
| Volume (1,000s): | 672.88 |
| Average Volume (1,000s): | 1,305.81 |
| Market Cap (M): | $143.81 |
| 1/2/2024 Price: | $1.13 |
| Change Since Inception: | -7.96% |
ALX Oncology Holdings Inc.
323 Allerton Avenue
South San Francisco, CA 94080
United States
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications.